MOLECULAR QUALITY CONTROL MARKET ANALYSIS

Molecular Quality Control Market, By Product Type (Independent Control and Instrument Specific Control), By Analyte Type (Single-Analyte Controls and Multi-Analyte Controls), By Application (Infectious Disease Diagnostics, Oncology Testing, Genetic Testing, Microbiology, and Other Applications), By End Users (Clinical & Diagnostic Laboratories, Hospitals and Clinics, Academic and Research Institutes, Contract Research Organizations, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On November 6, 2024, Microbiologics, a global leader in infectious disease reference materials and contract research, announced the acquisition of SensID, a Germany-based manufacturer specializing in molecular diagnostics for oncology and precision medicine. This marks Microbiologics' first international location and strengthens its portfolio in oncology while maintaining leadership in infectious disease diagnostics.
On June 11, 2024, Bio-Rad Laboratories, a life science company, expanded its molecular quality control portfolio with the launch of Exact Diagnostics GBS Positive and Negative Run Controls. These ready-to-use controls are designed for Group B Streptococcus (GBS) molecular assays to evaluate assay performance, operator proficiency, and workflow accuracy.
In February 2022, ZeptoMetrix, an Antylia Scientific company, launched the SARS-CoV-2 Omicron Control, expanding its infectious disease quality control portfolio. The product, now available for pre-order, supports reliable testing by addressing Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2 mutations.
On November 18, 2021, Roche, a pharmaceutical company, introduced the cobas 5800 System, a compact molecular laboratory instrument, in CE-mark-accepting countries. Designed to meet growing testing demands, it offers timely and reliable results, supports diverse testing needs, and helps laboratories manage increasing workloads and reimbursement complexities.